v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Concentration Risk [Line Items]          
Unbilled receivables $ 154,900   $ 154,900   $ 155,100
Rebate receivable 37,700   37,700   35,300
Investments in equity-method investees 30,200   30,200   $ 27,900
Equity in earnings of joint ventures $ 1,700 $ 1,400 3,393 $ 3,124  
Distributions received from the investees     $ 1,100 $ 1,600  
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 13.00% 12.00% 13.00% 12.00%  
Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent)     13.00%   13.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 57.00% 59.00% 57.00% 67.00%  
Largest Payer | Revenue from Contract with Customer Benchmark | Company's Largest Payer          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 14.00% 15.00% 14.00% 15.00%  
Joint Venture          
Concentration Risk [Line Items]          
Distributions received from the investees $ 1,100 $ 1,600 $ 1,100 $ 1,600